A Phase 1, Multinational Study of MCLA-117 in Acute Myelogenous Leukemia

Trial Profile

A Phase 1, Multinational Study of MCLA-117 in Acute Myelogenous Leukemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs MCLA 117 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man
  • Sponsors Merus
  • Most Recent Events

    • 19 Sep 2017 According to a Merus media release, the company is continuing the dose escalation of the trial for MCLA-117 in Europe and expects to submit an IND application to the U.S. Food and Drug Administration in the fourth quarter of 2017.
    • 11 Jul 2017 According to a Merus media release, this study is being conducted in Europe under a Clinical Trial Application (CTA). The company is planning to file an IND to the US FDA for this trial during the second half of 2017.
    • 11 Jul 2017 Merus expects to complete the dose escalation phase of Phase 1 portion during the second half of 2017, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top